Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
87 hedge funds and large institutions have $82.4M invested in Navidea Biopharmaceuticals Inc. in 2014 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 8 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
5% more funds holding
Funds holding: 83 → 87 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less capital invested
Capital invested by funds: $100M → $82.4M (-$18M)
99% less call options, than puts
Call options by funds: $95K | Put options by funds: $9.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Platinum Management
New York
|
+$1.36M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$511K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$334K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$229K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$255K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$251K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$241K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$196K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$162K |
NAVB Hedge Fund Activity: Q2 2014 in Review
87 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2014, worth a combined $82.4M — down 18% from $100M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NAVB positions and 8 closed out — a net gain of 4 holders — while 33 added to existing stakes and 18 trimmed.
The largest buyer was Platinum Management, adding an estimated $1.36M. The largest seller was Stoneridge Investment Partners, exiting entirely with an estimated $255K sold.
- 87 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2014, up from 83 in Q1 2014.
- Funds reported $82.4M of Navidea Biopharmaceuticals Inc. stock for Q2 2014, down 18% quarter-over-quarter.
- 12 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2014 and 8 closed out, a net change of +4 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2014 was Platinum Management, an estimated $1.36M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q2 2014 was Stoneridge Investment Partners, an estimated $255K sold.
Based on aggregated 13F filings for Q2 2014.